Centre Hospitalier Bethune Beuvry — Clinical Trial Site

21 Registered trials

13 Currently recruiting

Organisation

Centre Hospitalier Bethune Beuvry

Location

Beuvry, France

Identifier

ORG-100042395

Address

27 Rue Delbecque, 62660, France

Departments

Digestive oncology
Gastroenterolgy
Gastroenterology
Hépato-gastroenterologie
Hepatogastroenterology
ICU
Medical Oncology
Néphrologie
Neurology
Oncologie Médicale
Oncology
Oncology-Radiotherapy
Radiotherapy
Réanimation
Service de maladies infectieuses
Service de Médecine Intensive Réanimation
Service de réanimation polyvalente

Clinical trials at this site (21)

Search interface

RIFAMAB : Rifabutin versus rifampicin, staphylococcal prosthetic joint infection, multicenter randomized, open-label, non-inferiority trial Pending

2024-519894-20-01 Adult with an staphylococcal prosthetic joint infection 5
PRODIGE 88-CIRCULATE PAC: Phase III multicentric, open-label, randomized study to investigate the efficacy of chemotherapy in patients with … Recruiting

2023-505046-26-00 Colon carcinoma 5 2026-05-07
SAFE-ESO_Phase II study evaluating safety and efficacy of Tislelizumab for elderly patients unfit for chemotherapy, with advanced esophageal… Recruiting

2024-518358-17-00 Squamous cell carcinoma of the esophagus 4 2025-10-06
ENGIC 01 - COLOSOTO: A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) … Recruiting

2024-514030-20-00 colorectal cancer 4 2025-08-29
Safety and efficacy of apixaban versus warfarin in peritoneal dialysis patients with non valvular atrial fibrillation: a randomized controll… Recruiting

2023-507544-37-00 patients with end-stage renal disease on chronic perito 5 2025-01-08
Multicenter randomized, double-blind, placebo controlled trial evaluating the effect of a 30-week caffeine treatment on cognition in early-t… Recruiting

2024-514099-41-00 Alzheimer's disease 5 2024-10-31
PRODIGE 98- AMPIRINOX : Randomized, multicenter, Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or ge… Recruiting

2024-511070-68-01 Ampullary adenocarcinoma 5 2024-09-24
PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Recruiting

2024-515297-27-00 colon carcinoma 5 2024-08-14
FFCD 2006 – NEORAF : A MULTI-CENTRE, OPEN-LABEL, PILOT TRIAL EVALUATING THE COMBINATION ENCORAFENIB AND CETUXIMAB IN A NEOADJUVANT SETTING I… Recruiting

2024-514107-34-00 BRAF V600E-MUTATED LOCALISED COLON OR UPPER RECTUM CANC 4 2024-07-18
An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi… Recruiting

2022-501453-36-00 Breast cancer 5 2024-02-23
Efficacy of early intravenous high-dose vitamin C in post-cardiac arrest shock: a multicenter, randomized controled to standard treatment, o… Recruiting

2022-500717-64-00 cardiac arrest 4 2023-12-27
Oxaliplatin ± nivolumab in combination with trifluridine/tipiracil or 5- fluorouracile ± nivolumab in frail patients with advanced, recurren… Recruiting

2024-512999-35-00 Patients with HER 2 negative locally advanced, recurren 4 2023-06-23
Piperacillin-tazobactam and temocillin as carbapenem-alternatives for the treatment of severe infections due to extended-spectrum beta-lacta… Recruiting

2024-511866-36-00 patients hospitalized in ICU with ESBL-producing Entero 5 2023-03-11
Randomized phase 3 trial comparing FOLFOX to gemcitabine in metastatic first-line in patients with pancreatic adenocarcinoma and non-fit for… Recruiting

2024-511904-18-00 Pancreatic adenocarcinoma (PAC) 10 2020-07-08
PRODIGE 85 (FFCD 1804) – KANALRAD Prospective randomized phase III study evaluating induction chemotherapy (modified DCF 4 cycles) followed… Ended

2023-505972-32-00 locally advanced anal squamous cell carcinoma 5 2024-02-26
PRODIGE 81-FFCD 2101-TRIPLET: Study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patien… Ended

2022-501217-31-00 Hepatocellular carcinoma 10 2023-03-09
Randomized trial evaluating the addition of nivolumab to cisplatin-radiotherapy combination for treatment of cancers of the head and neck Ended

2024-513206-65-00 resected squamous cell carcinoma of head and neck 5 2018-08-10
Randomized trial of avelumab-cetuximab-Radiotherapy versus standards of care in the head and neck cancers Ended

2024-513964-24-00 Squamous cell carcinoma, previously untreated Stage III 5 2017-09-14
Adjunctive DobutAmine in sePtic cardiomyopathy with Tissue hypoperfusion: a randomized controlled multi-center trial Ended

2024-517839-50-00 sepsis 11 2020-09-20
EQU-001 as an Add-On Drug for People with Focal Seizures while on Medication Ended

2022-500302-18-00 Epilepsy 4
Does high-dose vitamin B3 supplementation prevent major adverse kidney events during septic shock? A multicenter randomized controlled study Ended

2024-517055-13-00 adverse kidney events during septic shock 5